Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393387 · ClinicalTrials.gov registry record
Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States
A clinical trial, sponsored by Midway Specialty Care Center.
- Completed
- Registry status
- 800
- Enrollment target
NCT06393387 is a clinical trial that has completed, run by Midway Specialty Care Center. The registered enrollment target is 800 participants.
The verdict
NCT06393387 has completed, sponsored by Midway Specialty Care Center.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
Study Summary
This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States
Interventions
- DRUG DTG/3TC versus BIC/F/TAF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2025-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06393387
The ClinicalTrials.gov registry entry for NCT06393387 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midway Specialty Care Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DTG/3TC versus BIC/F/TAF is the first listed.
NCT06393387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06393387 about?
NCT06393387 is a clinical study titled "Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States". This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States
What is the current status of trial NCT06393387?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2024-06-01. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT06393387?
The interventions under investigation include: DTG/3TC versus BIC/F/TAF (DRUG).
Who is sponsoring clinical trial NCT06393387?
This trial is sponsored by Midway Specialty Care Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.